40-Gene Expression Profile Predicts Local Recurrence in High-Risk cSCC

WEDNESDAY, July 30, 2025 (HealthDay News) -- The 40-gene expression profile (GEP) stratifies local recurrence-free survival (LRFS) and metastasis-free survival (MFS) in patients with National Comprehensive Cancer Network (NCCN) high-risk (HR) cutaneous squamous cell carcinoma (cSCC) who have negative margins after surgical resection, according to a study published in the July issue of SKIN.Désirée Ratner, M.D., from the NYU Grossman School of Medicine in New York City, and colleagues validated use of the 40-GEP to identify patients with NCCN HR cSCC who had negative margins after surgical resection and have an increased risk for LR and metastasis. Data were included from 414 patients with definitive negative margin Mohs surgery from a previously published cohort who were analyzed for risk prediction of LRFS and MFS.The researchers found that 40-GEP stratified patients, with higher three-year LRFS and MFS for low-risk class 1 patients versus class 2A or class 2B patients (LRFS: 95.3 versus 85.5 versus 71.4 percent; MFS: 97.1 versus 89.3 versus 57.1 percent, respectively). LRFS and MFS could not be stratified by the Brigham and Women's Hospital and American Joint Committee on Cancer staging systems. Significant predictors of LR risk included class 2A, class 2B, perineural invasion, and immunosuppression."The results of this study therefore validate the extended utility of the 40-GEP test within the NCCN HR patient cohort by providing information that not only predicts metastasis and response to adjuvant radiation therapy but also extends to prediction of LR," the authors write.Several authors disclosed ties to Castle Biosciences, which funded the study.Abstract/Full Text (subscription or payment may be required).Sign up for our weekly HealthDay newsletter

40-Gene Expression Profile Predicts Local Recurrence in High-Risk cSCC

Related Stories